The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
Seeking Alpha / 15 hours ago 3 Views
The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043
Comments